Premium
Response to thalidomide in chemotherapy‐resistant mantle cell lymphoma: a case report
Author(s) -
Wilson Edward A.,
Jobanputra Shialesh,
Jackson Robert,
Parker Anne N.,
McQuaker I. Grant
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03810.x
Subject(s) - mantle cell lymphoma , thalidomide , lymphoma , medicine , chemotherapy , rituximab , oncology , mantle (geology) , cancer research , multiple myeloma , biology , paleontology
Summary. Mantle cell lymphoma is an aggressive B‐cell lymphoma with a poor median survival despite conventional therapy. Here, we present the case of a patient with multiply relapsed mantle cell lymphoma, having failed treatment with chemotherapy, steroids and rituximab. He was treated with single‐agent thalidomide at a dose of 800 mg daily and entered a good partial remission which was maintained for the next 6 months. There is clearly a need for further studies of thalidomide in mantle cell lymphoma to confirm this promising initial result.